Posted by Michael Wonder on 26 Jan 2017
U.S. FDA approves 72 mcg dose of Linzess (linaclotide) for adults with chronic idiopathic constipation
26 January 2017 - New dosage strength expected to be available in first quarter of 2017.
Ironwood Pharmaceuticals and Allergan announced today that the U.S. FDA has approved a 72 mcg dose of Linzess (linaclotide) for the treatment of chronic idiopathic constipation (CIC) in adult patients.
Linzess is now FDA approved in three dosage strengths: 290 mcg for adult patients with irritable bowel syndrome with constipation, and 145 mcg and a new 72 mcg for the treatment of adults with CIC.
